REFERENCES

• SpearBB.Heath-ChiozziM.HuffJ.Clinical application of pharmacogenetics.Trends Mol Med.2001720120411325631
   PubMed Web of Science ®Google Scholar
• LazarouJ.PomeranzBH.CoreyPN.Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA.1998279120012059555760
   PubMed Web of Science ®Google Scholar
• HamburgMA.CollinsFS.The path to personalized medicine.N Engl J Med.201036330130420551152
   PubMed Web of Science ®Google Scholar
• VogelF.Moderne probleme der humangenetik.Ergebn Inn Med Kinderheilkd.19591252125
   Google Scholar
• Gonzalez de CastroD.ClarkePA.Al-LazikaniB.WorkmanP.Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.Clin Pharmacol Ther.20139325225923361103
   PubMed Web of Science ®Google Scholar
• VojvodaD.GrimmellK.SernyakM.MazureCM.Monozygotic twins concordant for response to clozapine.Lancet.1996347618531572
   PubMed Web of Science ®Google Scholar
• MataI.MadozV.ArranzMJ.ShamP.MurrayRM.Olanzapine: concordant response in monozygotic twins with schizophrenia.Br J Psychiatry.20011788611136224
   PubMed Web of Science ®Google Scholar
• PareCM.ReesL.SainsburyMJ.Differentiation of two genetically specific types of depression by the response to anti-depressants.Lancet.196221340134313941389
   PubMed Web of Science ®Google Scholar
• FranchiniL.SerrettiA.GasperiniM.SmeraldiE.Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.J Psychiatr Res.1998322552599789202
   PubMed Web of Science ®Google Scholar
• GrofP.DuffyA.CavazzoniP.et alIs response to prophylactic lithium a familial trait?J Clin Psychiatry.20026394294712416605
   PubMed Web of Science ®Google Scholar
• MalhotraAK.CorrellCU.ChowdhuryNl.et alAssociation between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.Arch Gen Psychiatry.20126990491222566560
   PubMed Web of Science ®Google Scholar
• RavynD.RavynV.LowneyR.NasrallahHA.CYP450 Pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.Schizophr Res.201314911423870808
   PubMed Web of Science ®Google Scholar
• ZhangJP.MalhotraAK.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Expert Opin Drug Metab Toxicol.2011793721162693
   PubMed Web of Science ®Google Scholar
• LeckbandSG.KelsoeJR.DunnenbergerHM.et alClinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Clin Pharmacol Ther.20139432432823695185
   PubMed Web of Science ®Google Scholar
• GuengerichFP.Cytochrome P450 and chemical toxicology.Chem Res Toxicol.200821708318052394
   PubMed Web of Science ®Google Scholar
• HiemkeC.BaumannP.BergemannN.et alAGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011 .Pharmacopsychiatry.201144195235
   Web of Science ®Google Scholar
• HicksJK.SwenJJ.ThornCF.et alClinical Pharmacogenetics implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Clin Pharmacol Ther.20139340240823486447
   PubMed Web of Science ®Google Scholar
• CacabelosR.HashimotoR.TakedaM.Pharmacogenomics of antipsychotics efficacy for schizophrenia.Psychiatry Clin Neurosci.20116531921265934
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2013) Table of pharmacogenomic biomarkers in drug labels Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed June 2014.
   Google Scholar
• RasmussenBB.BrixTH.KyvikKO.BrosenK.The interindividual differences in the 3-demthylation of caffeine alias CYP1 A2 is determined by both genetic and environmental factors.Pharmacogenetics.20021247347812172216
   PubMedGoogle Scholar
• PereraV.GrossAS.M PolasekT.et alConsidering CYP1 A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Expert Opin Drug Metab Toxicol.201391115113723641727
   PubMed Web of Science ®Google Scholar
• Kootstra-RosJE.SmallegoorW.van derWeide J.The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients.Ann Clin Biochem.20054221621915949157
   PubMed Web of Science ®Google Scholar
• JaquenoudSirot E.KnezevicB.MorenaGP.et alABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.J Clin Psychopharmacol.20092931932619593168
   PubMed Web of Science ®Google Scholar
• NozawaM.OhnumaT.MatsubaraY.et alThe relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).Ther Drug Monit.200830354018223460
   PubMed Web of Science ®Google Scholar
• GhotbiR.MannheimerB.AklilluE.SudaA.BertilssonL.EliassonE.OsbyU.Carriers of the UGT1A4 142T <G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients.Eur J Clin Pharmacol.20106646547420143052
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergM.Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.Naunyn Schmiedebergs Arch Pharmacol.20043698910414574440
   PubMed Web of Science ®Google Scholar
• OzdemirV.KalowW.TangBK.PatersonAD.WalkerSE.EndrenyiL.KashubaAD.Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.Pharmacogenetics.20001037338810898107
   PubMedGoogle Scholar
• DuJ.ZhangA.WangL.et alRelationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.J Psychopharmacol.2010241115112019395426
   PubMed Web of Science ®Google Scholar
• DomanskiTL.FintaC.HalpertJR.ZaphiropoulosPG.cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.Mol Pharmacol.20015938639211160876
   PubMed Web of Science ®Google Scholar
• BigosKL.BiesRR.PollockBG.LowyJJ.ZhangF.WeinbergerDR.Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Mol Psychiatry.20111662062521519338
   PubMed Web of Science ®Google Scholar
• BrandlEJ.ChowdhuryNi.TiwariAK.LettTAP.MeltzerHYM.KennedyJL.MullerDJ.Genetic variation in CYP3A43 gene is associated with response to antipsychotic medication.J Neural Transm. In press.
   Google Scholar
• MoonsT.de RooM.ClaesS.DomG.Relationship between P-glycoprotein and second-generation antipsychotics.Pharmacogenomics.2011121193121121843066
   PubMed Web of Science ®Google Scholar
• WongM.EvansS.RivoryLP.et alHepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.Clin Pharmacol Ther.200577334215637529
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyC.OhJM.KimIW.SaunaZE.CalcagnoAM.AmbudkarSV.GottesmanMM.A “silent” polymorphism in the MDR1 gene changes substrate specificity.Science.200731552552817185560
   PubMed Web of Science ®Google Scholar
• KapurS.SeemanP.Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis.Am J Psychiatry.200115836036911229973
   PubMed Web of Science ®Google Scholar
• JafariS.Fernandez-EnrightF.HuangXF.Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.J Neurochem.201212037138422103329
   PubMed Web of Science ®Google Scholar
• ZhangJP.LenczT.MalhotraAK.D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Am J Psychiatry.201016776377220194480
   PubMed Web of Science ®Google Scholar
• HwangR.ZaiC.TiwariA.et alEffect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant.Pharmacogenomics J.20101020021820029384
   PubMed Web of Science ®Google Scholar
• ReynoldsGP.ArranzB.TemplemanLA.FertuzinhosS.SanL.Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients.Am J Psychiatry.20061631826182917012696
   PubMed Web of Science ®Google Scholar
• WangL.FangC.ZhangA.et alThe -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.J Psychopharmacol.20082290490918308786
   PubMed Web of Science ®Google Scholar
• MossnerR.SchuhmacherA.KuhnKU.et alFunctional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.Pharmacogenet Genomics.200919919418849890
   PubMed Web of Science ®Google Scholar
• ArranzMJ.MunroJ.ShamP.et alMeta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.Schizophr Res.19983293999713904
   PubMed Web of Science ®Google Scholar
• LiM.LuoXJ.XiaoX.et alAllelic differences between Han Chinese and Europeans for functional variants in ZNF804A and their association with schizophrenia.Am J Psychiatry.20111681318132521890790
   PubMed Web of Science ®Google Scholar
• RileyB.ThiseltonD.MaherBS.et alReplication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample.Mol Psychiatry.201015293719844207
   PubMed Web of Science ®Google Scholar
• EsslingerC.WalterH.KirschP.et alNeural mechanisms of a genomewide supported psychosis variant.Science.200932460519407193
   PubMed Web of Science ®Google Scholar
• XiaoB.LiW.ZhangH.et alTo the editor: association of ZNF804A polymorphisms with schizophrenia and antipsychotic drug efficacy in a Chinese Han population.Psychiatry Res.201119037938121663974
   PubMed Web of Science ®Google Scholar
• ZhangJ.WuX.DiaoF.GanZ.ZhongZ.WeiQ.GuanN.Association analysis of ZNF804A (zinc finger protein 804A) rs1344706 with therapeutic response to atypical antipsychotics in first-episode Chinese patients with schizophrenia.Compr Psychiatry.2012531044104822425527
   PubMed Web of Science ®Google Scholar
• MossnerR.SchuhmacherA.WagnerM.et alThe schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms.Eur Arch Psychiatry Clin Neurosci.201226219319721892778
   PubMed Web of Science ®Google Scholar
• CramerJA.RosenheckR.Compliance with medication regimens for mental and physical disorders.Psychiatr Serv.1998491962019575004
   PubMed Web of Science ®Google Scholar
• KampmanO.LaippalaP.VaananenJ.KoivistoE.KiviniemiP.KilkkuN.LehtinenK.Indicators of medication compliance in first-episode psychosis.Psychiatry Res.2002110394812007592
   PubMed Web of Science ®Google Scholar
• PerkinsDO.GuH.BotevaK.LiebermanJA.Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.Am J Psychiatry.20051621785180416199825
   PubMed Web of Science ®Google Scholar
• LiebermanJA.StroupTS.McEvoyJP.et alEffectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med.20053531209122316172203
   PubMed Web of Science ®Google Scholar
• ZhangJP.MalhotraAK.Pharmacogenetics of antipsychotics: recent progress and methodological issues.Expert Opin Drug Metab Toxicol.2013918319123199282
   PubMed Web of Science ®Google Scholar
• ChowdhuryNl.TiwariAK.SouzaRP.et alGenetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene.Pharmacogenomics J.20131327227922310352
   PubMed Web of Science ®Google Scholar
• CzerwenskyF.LeuchtS.SteimerW.Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain.J Clin Psychopharmacol.201333747923277235
   PubMed Web of Science ®Google Scholar
• CzerwenskyF.LeuchtS.SteimerW.MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?Int J Neuropsychopharmacol.2013162103210923920449
   PubMed Web of Science ®Google Scholar
• AlvirJM.LiebermanJA.SaffermanAZ.SchwimmerJL.SchaafJA.Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.N Engl J Med.19933291621678515788
   PubMed Web of Science ®Google Scholar
• GrunderG.HippiusH.CarlssonA.The 'atypicality' of antipsychotics: a concept re-examined and re-defined.Nat Rev Drug Discov.2009819720219214197
   PubMed Web of Science ®Google Scholar
• MeltzerHY.Clozapine: balancing safety with superior antipsychotic efficacy.Clin Schizophr Relat Psychoses.2012613414423006238
   PubMedGoogle Scholar
• AthanasiouMC.DettlingM.CascorbiI.et alCandidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapineinduced agranulocytosis.J Clin Psychiatry.20117245846320868635
   PubMed Web of Science ®Google Scholar
• TiwariAK.NeedAC.LohoffFW.et alExome sequence analysis of Finnish patients with clozapine-induced agranulocytosis.Mol Psychiatry.20141940340523752246
   PubMed Web of Science ®Google Scholar
• MargoleseHC.ChouinardG.KolivakisTT.BeauclairL.MillerR.AnnableL.Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Can J Psychiatry.20055070371416363464
   PubMed Web of Science ®Google Scholar
• FleemanN.DundarY.DicksonR.et alCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Pharmacogenomics J.20111111420877299
   PubMed Web of Science ®Google Scholar
• ZaiCC.De LucaV.HwangRW.VoineskosA.MüllerDJ.RemingtonG.KennedyJL.Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.Mol Psychiatry.20071279479517767146
   PubMed Web of Science ®Google Scholar
• LererB.SegmanRH.TanEC.et alCombined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.Int J Neuropsychopharmacol.2005841142515857569
   PubMed Web of Science ®Google Scholar
• SyuA.IshiguroH.InadaT.et alAssociation of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.Neuropsychopharmacology2010351155116420072119
   PubMed Web of Science ®Google Scholar
• GreenbaumL.AlkelaiA.ZozulinskyP.KohnY.LererB.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.Pharmacogenomics J.20121251352021808285
   PubMed Web of Science ®Google Scholar
• LanktreeMB.ZaiG.VanderbeekLE.et alPositive perception of pharmacogenetic testing for psychotropic medications.Hum Psychopharmacol.20142928729124604560
   PubMed Web of Science ®Google Scholar
• CrettolS.de LeonJ.HiernkeC.EapCB.Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.Clin Pharmacol Ther.20149525425724196844
   PubMed Web of Science ®Google Scholar
• DunbarL.ButlerR.WheelerA.PulfordJ.MilesW.SheridanJ.Clinician experiences of employing the AmpliChip(R) CYP450 test in routine psychiatric practice.J Psychopharmacol.20122639039719942639
   PubMed Web of Science ®Google Scholar
• de LeonJ.SusceMT.PanRM.FairchildM.KochWH.WedlundPJ.The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.J Clin Psychiatry.200566152715669884
   PubMed Web of Science ®Google Scholar
• MullerDJ.BrandlEJ.HwangR.et alThe AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.Genet Test Mol Biomarkers.20121689790322775532
   PubMed Web of Science ®Google Scholar
• WinnerJ.AllenJD.AltarCA.Spahic-MihajlovicA.Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression.Transl Psychiatry.20133e24223511609
   PubMed Web of Science ®Google Scholar
• Hall-FlavinDK.WinnerJG.AllenJD.et alUsing a pharmacogenomic algorithm to guide the treatment of depression.Transl Psychiatry.20122e17223047243
   PubMed Web of Science ®Google Scholar
• RipkeS.O'DushlaineC.ChambertK.et alGenome-wide association analysis identifies 13 new risk loci for schizophrenia.Nat Genet.2013451150115923974872
   PubMed Web of Science ®Google Scholar
• RellingMV.KleinTE.CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.Clin Pharmacol Ther.20118946446721270786
   PubMed Web of Science ®Google Scholar
• AltmanRB.Pharmacogenomics: “noninferiority” is sufficient for initial implementation.Clin Pharmacol Ther.20118934835021326263
   PubMed Web of Science ®Google Scholar
• MrazekDA.LermanC.Facilitating clinical implementation of pharmacogenomics.JAMA.201130630430521771991
   PubMed Web of Science ®Google Scholar
• HiemkeC.PfuhlmannB.Interactions and monitoring of antipsychotic drugs.Handb Exp Pharmacol.201224126523129335
   PubMedGoogle Scholar
• ArinamiT.GaoM.HamaguchiH.ToruM.Afunctional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.Hum Mol Genet.199765775829097961
   PubMed Web of Science ®Google Scholar
• JeanneteauF.FunalotB.JankovicJ.DengH.LagardeJP.LucotteG.SokoloffP.Afunctional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor.Proc Natl Acad Sci U S A.2006103107531075816809426
   PubMed Web of Science ®Google Scholar
• LemondeS.TureckiG.BakishD.et alImpaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide.J Neurosci.2003238788879914507979
   PubMed Web of Science ®Google Scholar
• PolesskayaOO.AstonC.SokolovBP.Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNAmethylase DNMT1.J Neurosci Res.20068336237316358338
   PubMed Web of Science ®Google Scholar
• HazelwoodLA.Sanders-BushE.His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation.Mol Pharmacol.2004661293130015496511
   PubMed Web of Science ®Google Scholar
• HillMJ.ReynoldsGP.Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain.Pharmacogenomics.20111272773421391883
   PubMed Web of Science ®Google Scholar
• HillMJ.ReynoldsGP.5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity.Brain Res.20071149141717376412
   PubMed Web of Science ®Google Scholar
• YuanX.YamadaK.Ishiyama-ShigemotoS.KoyamaW.NonakaK.Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes.Diabetologia.20004337337610768099
   PubMed Web of Science ®Google Scholar
• BucklandPR.HoogendoornB.GuyCA.SmithSK.ColemanSL.O'DonovanMC.Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain.Am J Psychiatry.200516261361515741483
   PubMed Web of Science ®Google Scholar
• SimSC.Ingelman-SundbergM.The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.Hum Genomics.2010427828120511141
   PubMedGoogle Scholar
• PohjalainenT.RinneJO.NagrenK.LehikoinenP.AnttilaK.SyvalahtiEK.HietalaJ.The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.Mol Psychiatry.199832562609672901
   PubMed Web of Science ®Google Scholar
• RitchieT.NobleEP.Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics.Neurochem Res.200328738212587665
   PubMed Web of Science ®Google Scholar
• PolesskayaOO.SokolovBP.Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics.J Neurosci Res.20026781282211891796
   PubMed Web of Science ®Google Scholar
• KhaitVD.HuangYY.ZalsmanG.OquendoMA.BrentDA.HarkavyFriedmanJM.MannJJ.Association of serotonin 5-HT2A receptor binding and the T102C polymorphism in depressed and healthy Caucasian subjects.Neuropsychopharmacology20053016617215483560
   PubMed Web of Science ®Google Scholar
• Whirl-CarrilloM.McDonaghEM.HebertJM.et alPharmacogenomics knowledge for personalized medicine.Clin Pharmacol Ther.20129241441722992668
   PubMed Web of Science ®Google Scholar
• CaudleKE.KleinTE.HoffmanJM.et alIncorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Curr Drug Metab.20141520921724479687
   PubMed Web of Science ®Google Scholar